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Background
Simplification of antitretroviral treatment (ARV) is parti-
cularly important. If darunavir/ritonavir (DRV/r) can be
used at a 800/100mg once a day (q.d.) on patients with
a wild-type virus, it is recommended at a 600/100mg
twice a day (b.i.d.) on pre-treated patients. POWER
study suggests the similarity of efficiency of the 800/100
mg q.d. and 600/100mg b.i.d. in patients with a minimal
number of DRV resistance mutations.
Objectives
Evaluate the capacity of DRV/r(900/100mg) q.d. to
maintain viral load(VL) indetectability at W24, after
switch from DRV/r 600/100mg bid, in virologically
supressed pre-treated HIV-1 patients.
Methodology
This observational study included 45 patients if they had
a VL<50copies/ml and a steady treatment associating
DRV/r 600/100 mg b.i.d. with INTI and/or INNTI. A
genotypic test was perform on the plasmatic HIV-1
RNA, on the last detectable VL (>50cp/ml) before start-
ing DRV, and in case of virological failure. The follow
up is done at D0, W4/W12/W24/W36 and W48 includ-
ing VL measure, CD4 cells count, residual plasmatic
concentrations of darunavir and ritonavir. Virological
failure was defined as two consecutives VL >50cp/ml at
a minimal 15 days interval. The primary endpoint was
the proportion of patients with a VL <50cp/ml at W24.
Results
Between 02/2008 and 02/2009, 45 patients were
included with an anterior ARV treatment of 13[1,20]
years, with exposure to 3 ARV classes among 34( 75%)
patients and a previous failure ≥ 2 PI for 20(44%)
patients. CD4 cell count was 478/mm
3 [317-560]; nadir
CD4: 93/mm
3 [39-165].They were treated by DRV/r b.i.
d. since 10[3;44] months. DRV/r was associated with: 2
INTI (76%), 3 INTI (8%), 2 INTI/1INNTI( 5%). 93%
plasmatic RNA genotypic tests were amplified. Five
patients had ≥ 3 DRV impacting resistance mutations,
six patients 2 mutations, and nine patients 1 mutation.
The proportion of patients with VL<50cp/mL[IC95] at
W24 was 93%[81-98] and 91%[78-97] at W48, in ITT
and PP analysis.
Three virological failures were observed at W12 and
one at W48. For 1 patient, 2 primary PI mutations
(I50V and L33F) were observed.
Conclusion
This study suggests that DRV/r can be used once a day
even for patients with a previous IP failure. This
approach is particularly important for the once daily use
of combination INTI. It also enables a reduction of the
ritonavir dose.
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